WorldCat Identities

Schweizerische Nationalliga für Krebsbekämpfung und Krebsforschung

Works: 101 works in 214 publications in 2 languages and 6,834 library holdings
Genres: Conference papers and proceedings 
Roles: Editor, Other
Classifications: RC261, 616.994008 S
Publication Timeline
Most widely held works about Schweizerische Nationalliga für Krebsbekämpfung und Krebsforschung
Most widely held works by Schweizerische Nationalliga für Krebsbekämpfung und Krebsforschung
Aging and cancer by Frederick F Holmes( Book )

2 editions published in 1983 in English and held by 211 WorldCat member libraries worldwide

The life of a human being is finite, and all humans age (see Fries 1980). It is difficult to separate the effects of disease on organs and tissues from those expected of aging. This is particularly true for vascular and degenerative processes, for which there are no clear boundaries between aging and disease. Morbidity and mortality from heart disease and stroke are probably due both to disease and to changes of aging. For cancer, the second leading cause of death in America, the situation is quite different; cancer is clearly a disease and is not a change expected with aging. Cancer incidence increases almost logarithmically after age 40. In the United States about one-half of all cases of cancer are diagnosed after age 65, although those over 65 comprise less than one-eighth of the population. Thus, cancer is very much a disease of the elderly. There are at least two reasons for this: first, the prolonged exposure to cancer-inducing agents, and second, the waning power of immune defenses against cancer
Investigation and stimulation of immunity in cancer patients by Georges Mathé( Book )

5 editions published in 1974 in English and held by 193 WorldCat member libraries worldwide

G. MATHE Institut de Cancerologie et d'Immunogenetique (INSERM et Association Claude-Bernad), H6pital Paul-Brousse and Institute Gustave-Roussy, Villejuif 20 years ago, the main, if not only object of the cancer therapist was to effect complete surgical exeresis or radiotherapeutic destruction of a local tumor, or to obtain, by means of chemotherapy, an "apparently complete regression" of a local or disseminated neoplasia. Today it is realized that (a) at the time of the operation or radiotherapy, two patients in every three carrying an apparently localized tumor have a few cancer cells outside the area where the tumor seems localized; (b) when "apparently complete regression" or even an "apparently complete remission" is induced by chemotherapy, not all the neoplastic cells have been eradicated. In both cases an imperceptible residual neoplasm persists, the growth of which will in due course make it perceptible again, giving rise to metastasis or to a systemic or localized relapse. There is thus an urgent need for a new technique capable of killing the last cell or cells. Our experiments in mice on the effectiveness of active immunotherapy, which involves the manipulation of the immune machinery, have shown that this treatment is able to kill all the cells, down to the very last cell of a given leukemia, provided that the total number of cells does not exceed a few thousand [1, 2]
Lung cancer by William Duncan( Book )

3 editions published in 1984 in English and held by 191 WorldCat member libraries worldwide

Each year a multidisciplinary symposium on Clinical Oncology is organised by the Royal College of Radiologists in London. The fifth symposium was held in February 1983 when the subject was Lung Cancer. The clinical and social importance of lung cancer cannot be too greatly stated. The disease is an enormous cause of morbidity and remains the most common cause of death from cancer in males in the Western World. Sadly, the incidence of the disease continues to increase in women in the United Kingdom, and the success of commercial pressure to encourage cigarette smoking in the developing countries must mean that an increasing community health problem may be anticipated. The methods used to promote cigarette smoking are dramatically described in this publication. The enormous weight of vested interest in tobacco consumption makes education of the public and of politi cians about the health hazards of smoking a formidable battle waged with very limited resources. Attitudes can be changed by skilled professional groups, but they do require much greater international support. The prognosis of patients with lung cancer remains extremely poor. Optimum management requires expert pretreatment assessment and careful selection of the many forms of treatment available. The techniques of clinical assessment and staging, radiological investiga- Preface VI tion, and pathological classification are all described in some detail and their limitations are well illustrated. It is hoped that meetings of this kind will stimulate the further collaboration of multidisciplinary groups to improve our understanding of these aggressive diseases
Antitumor antibiotics by Stephen K Carter( Book )

3 editions published in 1978 in English and held by 191 WorldCat member libraries worldwide

The scientific collaboration between the United States and Japan in the field of cancer goes back many years. In this successful international collaboration cancer chemotherapy has been one of the most productive areas. Pioneers such as YOSHIDA, UMEZAWA, SHEAR, and GOLDIN established firm links of mutual trust and respect in the period after the Second Great War. Japanese drugs, such as mitomycin C and bleomycin have become mainstays of clinical oncology in the U.S. and throughout the world. Many drugs developed in the U.S. have become established in Japanese cancer therapy. Within the cancer chemotherapy field the antitumor antibiotics rank as one of the most important groups. In the U . S.-J apanese collaboration this group of drugs has taken the paramount role. The Japanese, under the leadership of U mezawa, are considered to be among the most innovative and productive in this area which has also had great emphasis in the United States as part of the National Cancer Institute's drug development program and in the pharmaceutical industry. This extended collaboration in general oncology, and chemotherapy in particular, has received increased impetus by and support from the official U . S.-J apan Joint Agreement on cancer research, which was established in 1974 between the National Cancer Institute and the Japanese Society for the Promotion of Science. One of the subsections of this agreement is cancer therapy with emphasis on chemotherapy
Lymphocytes, macrophages, and cancer by Georges Mathé( Book )

2 editions published in 1976 in English and held by 190 WorldCat member libraries worldwide

Fresh living Bacillus Calmette-Guerin (BeG), injected i.v. into (C57BI/ 6xDBA/2)FI mice, activated peritoneal macrophages rendering them highly cytotoxic for tumor cells in vitro. This cytotoxic activity w~s already maximal 14 days after injection of 1 mg of BCG and remained stable when 3 or 5 mg of BCG were given. At the same time spleen cells of the BCG-treat~d mice showed strongly depressed responses to the T-cell mitogens, PHA and Con A, irrespective of the dose of BCG injected. The inhibitory effect was shown to be mediated by suppressor cells which had characteristics of macrophages since they could be removed by carbonyl iron and magnet treatment and were adherent to plastic. In contrast to it was observed after injec tion of 1 mg of BCG, these suppressor cells alone did not account for the depression of T-cell re.sponses induced by higher doses of BCG. Nylon-nonadherent cell populations obtained from spleen cells treated with 3 or 5 mg BCG partially retained the inhibitory activity suggesting that suppressor T cells were also induced after injection of high doses of BCG. In contrast, the responses to the B-cell mitogen LPS of unfractionated and macrophage-depleted spleen cells were not affected or significantly enhanced depending on the dose of BCG injected
Clinical interest of steroid hormone receptors in breast cancer by G Leclercq( Book )

3 editions published in 1984 in English and held by 186 WorldCat member libraries worldwide

Several papers dealing with the clinical relevance of steroid hormone receptors in breast cancer have already been published. However, no publication has overviewed studies currently being conducted in Europe, nor is there a register of the european centers performing receptor assays. It has been our purpose to fill these gaps. A large majority of authors who we contacted kindly agreed to con tribute to our book. Papers were grouped into six main parts according to their contents. The abundance of clinical data relevant to receptor assays led us to add critical summaries to help the reader to form his own opinions on the subject. We would like to thank Drs. R.J.B. King, G. Contesso, L. Santi, and E. Engelsman, who helped us in this regard. We hope that this book will enable the reader to become acquainted with the present state of European steroid hormone receptor studies devoted to breast cancer treatment. We also hope that it will promote cooperation between European oncologists involved in this field of research
New drugs in cancer chemotherapy by Stephen K Carter( Book )

3 editions published in 1981 in English and held by 185 WorldCat member libraries worldwide

The Analog Potential in Cancer Chemotherapy in the United States and Japan S.K. Carter Northern California Cancer Program, 1801 Page Mill Road, Building B, Suite 200, USA - Palo Alto, CA 94304 The bilateral collaborative program in cancer research between Japan and the United States is one of the oldest programs of this type. It is sponsored in the United States by the National Cancer Institute [1], while in Japan the sponsoring organization is the Japan Society for the Promotion of Science. Annual symposia concerning treatment have been held and in recent years they have been published [2, 3]. Drug development in both Japan and the United States has evolved over the years to an increasing emphasis on second generation compounds. This has come about as a result of the initial successes of chemotherapy development. Many active structures have been uncovered and the armamentarium of the medical and pediatric oncologist has grown dramatically. The uncovering of an active structure provides an opportunity for analog synthesis and attempts at elucidating structure-activity relationships. It is hoped that the therapeutic index of active structures can be improved so as to achieve superior clinical results
New anticancer drugs by Stephen K Carter( Book )

4 editions published between 1979 and 1980 in English and held by 182 WorldCat member libraries worldwide

Complications of cancer chemotherapy by Georges Mathé( Book )

5 editions published in 1974 in English and held by 182 WorldCat member libraries worldwide

G. MATHE and R.K. OLDHAM'~ Institut de Cancerologie et d'Immunogem!tique, Hopital Paul Brousse, Villejuif Since the last war, cancer chemotherapy has been the object of very intensive and expensive research. Nevertheless, its development has been very slow, and its ultimate potential is today somewhat in doubt. In doubt because it does not cure any cancer patients except a) females carrying placental choriocarcinoma, a semi-allogenic tumor, in which case, cure may be in fluenced by immune rejection, and b) children suffering from Burkitt's tumor, where the probable reason for the cure is that all the neoplastic cells are in the cycle, which is a unique condition among all the human tumor varieties. Whether the long term survivors in acute leukemia, lymphomas, certain sarcomas and certain testicular tumors are "cures" will require longer follow-up. The idea that chemotherapy does not cure most cancer patients because all their neoplastic cells are not in cycle has led to the use of drug combinations. Whatever they are, "cocktail combinations" which are made up of drugs given according to any timing, or scientific combinations, based on pharmacodynamics, pharmaco kinetics or cell kinetics data, are more toxic than single drugs, and are all the more toxic as the number of drugs in the combination is increased
Hairy-cell leukemia by J Burthem( Book )

3 editions published in 1980 in English and held by 180 WorldCat member libraries worldwide

Hairy cell Leukaemia (HCL) has always attracted an interest out of all proportion to its frequency and continues to do so. There are two reasons for this. The first is that the disease is unusually responsive to therapy and second is that it has provided a number of important insights into B-cell biology. This monograph is a comprehensive account of hairy cell leukaemia and aims to provide a more detailed account than is available in the existing literature. The work is timely because a consensus has now emerged concerning accurate differential diagnosis a nd curative treatment. These aspects therefore form the focus of the book and are considered in detail. The basic advances in the laboratory that encourage the belief that elucidation of the underlying oncogenic event in the disease may be within reach. The background to this belief is extensively renewed. As a result the monograph will be of interest and practical value to both clinicians and researchers in this and related fields
Lymphoid neoplasias by Georges Mathé( Book )

10 editions published in 1978 in English and held by 180 WorldCat member libraries worldwide

We have studied 24 cases of secondarily leukemic (stage V) lymphosarcoma (LS), 31 cases of "d'emblee" leukemic LS, and ten cases of lymphoid leukemic neoplasias transitional between "d'emblee" leukemic LS and chronic lymphocytic leukemia (eLL). These cases only concern the common types ofthe WHO classification ofLS, i.e., the prolymphocytic, the lymphoblastic, and the immunoblastic. Some cases have also been classified by cell surface markers. The secondarily leukemic conversion occurred in 40% of the lymphoblastic types, in 14% of the prolymphocytic types, and in 17% of the immunoblastic types. It never occurred at stage I but could occur after any other stage. The mediastinal involvement was observed in three types, but most often in the lymphoblastic type. The prognosis after an acute lymphoid leukemia (ALL) treatment comprising active immunotherapy following chemo(radio)therapy is better for the leukemic prolymphocytic and lymphoblastic LS than for the immunoblastic type. Two patients (one of the lymphoblastic type) are in complete remission after 8 and 5 years, respectively. We have described ten cases of "d'emblee" leukemic LS with either large lymphoid or extra lymphoid masses, bone marrow leukemic cell involvement, and LS aspects of neoplastic cells. Mediastinal, abdominal, or other tumor masses are frequent
Hereditary factors in carcinoma by Henry T Lynch( Book )

3 editions published in 1967 in English and held by 180 WorldCat member libraries worldwide

Endocrine treatment of breast cancer : a new approach by B Henningsen( Book )

3 editions published in 1980 in English and held by 179 WorldCat member libraries worldwide

Progress in basic research has made it necessary to redetermine the possibility of classic endocrine therapy for the treatment of patients with breast cancer. Exemplary, close cooperation between biochemis try and animal and clinical research led to a truly interdisciplinary and international exchange of ideas and experience at a symposium held in autumn 1978 in Heidelberg. We owe our thanks to ICI-Pharma for the kind support of this sym posIUm. The participation of Charles Huggins in the meeting as honorary chairman signified to all participants the meaning of this joint endeavour. It was the same Charles Huggins who through experimental work laid the foundation stone for endocrine ther apy of prostate and breast cancer, and who applied his findings clinically. Thousands of patients owe to him relief from their suffering. He contributed greatly to the attempt to find and stabilize the endocrine therapy for breast cancer, for which we thank him sincerely. We hope that the following contributions will similarly serve the well-being of our patients
Malignant transformation by viruses by W. H Kirsten( Book )

5 editions published in 1966 in English and held by 177 WorldCat member libraries worldwide

The position of "Cancer Teaching Coordinator" at The University of Chicago has been a consistently rewarding one because of the enthusiasm and support of the faculty and the students. This volume is the result of the second of two recent intensive teach ing sessions which have been planned and implemented by the group which forms the Cancer Coordinator's Advisory Committee. The first of these teaching sessions was held in early March of 1964 and was entitled "LEUKEMIA, A Current and Forward Look." It attracted overflow attendance from the students and staff of this medical institution augmented by members of the other medical centers in Chicago. It was a stimulating and instructive colloquium, and the only regret we heard expressed afterward was that we had not arranged for publication of the many excellent presentations. One of the events commemorating the seventy-fifth anniversary of the founding of The University of Chicago was this symposium on malignant transformations. This time the Committee advised us to plan on speedy publication, and, logically, it chose Dr. Werner Kirsten, a member of our faculty and an active and effective investigator in this general field of endeavor, to serve as editor of the volume. Again, two of the same ingredients for effective instruction were blended: an excellent group of scientists presenting their latest work and a fine, attentive audience of students and staff
Adjuvant chemotherapy of breast cancer by Hansjörg Senn( Book )

2 editions published in 1984 in English and held by 176 WorldCat member libraries worldwide

H.-J. Senn Adjuvant Chemotherapy (ACT) of breast cancer has now emerged as one of the controversial su):>jects in clinical and also experimental oncology. Driven by growing frustration about stagnating cure rates in breast cancer [1,4] and stimulated by elegant demonstration of highly curative effects of adjuvant systemic therapy in animal models [6, 11] and in several childhood neoplasias [15], researchers introduced ACT to the primary treatment of breast cancer with great hope some 15 years ago. After a first wave of isolated "historic" trials with generally limited but in one case remarkable success [5, 9], a second generation of ACT studies was initiated by NSABP investigators and oncology centers in Europe [2, 6, 13]. These trials were well conducted statistically and diagnostically, and all in the early 1970s included a surgical control arm. Early and intermediate beneficial effects on relapse-free survival (RFS) after 2-3 years median observation time then prompted a whole series of ACT studies in breast cancer. These "third-gener ation" studies usually regarded some positive influence of ACT as a given fact, dropping surgical control regimens and comparing different ACT regimens, hopefully in a prospective, randomized way 1984 Fig. 1. The mushrooming of adjuvant studies in breast cancer XII Introduction [reviews in 3, 14]. The "mushrooming" of ACT studies in breast cancer during the last 10 and especially 5 years is demonstrated in Fig. 1, and it gets really cumbersome even for the insider to keep on top of the multitude of sometimes conflicting data
Tactics and strategy in cancer treatment by European Organization for Research on Treatment of Cancer( Book )

4 editions published in 1977 in English and held by 172 WorldCat member libraries worldwide

Breast cancer, a challenging problem by Symposium on Breast Cancer - a Challenging Problem( Book )

7 editions published in 1973 in English and held by 168 WorldCat member libraries worldwide

This volume summarizes the proceedings of the fifth biennial Cancer Teaching Symposium held on March 4 and 5, 1972 at the University of Chicago Pritzker School of Medicine. The program was prepared by Drs. MELVIN GRIEM, ELWOOD JENSEN, HAROLD SUTTON, JOHN ULTMANN, and ROBERT WISSLER. The purpose of the symposium was to present the current status of the challenging cancer problem, breast carcinoma, to the staff and students of this medical center and to students and in terested physicians from other institutions in the Chicago area. In a fashion similar to the other teaching symposia held in 1964, 1966, 1968,. and 1970, this symposium attracted over 450 physicians and scientists. In the course of one and one half days the audience had the opportunity to listen to 18 invited speakers and to the lively discussions. The formal presentations are recorded in these pages. This teaching symposium could not have been undertaken without the faithful assistance of the program committee, the cancer training grant education committee, the staff who recorded and transcribed the proceedings, and the editorial assistants. We wish to thank the following for their efforts: JULIE KANT, Administrative Secre tary for the Clinical Cancer Training Grant, as well as Dr. JAMES MARKS, MARGARET WOEHRLE, FRIEDA RANNEY, and ROSIE BARTLETT. This symposium received financial support from USPHS Clinical Cancer Train ing Grant 5T12 CA-08077-06 and from the Chicago Tumor Institute. MELVIN L. GRIEM, M.D. ROBERT W. WISSLER, Ph. D., M.D
Scientific basis of cancer chemotherapy by Georges Mathé( Book )

5 editions published in 1969 in English and held by 150 WorldCat member libraries worldwide

Scientific Basis of Cancer Chemotherapy focuses on methods and approaches in the treatment of cancer, including detection, chemotherapeutic agents, and hormonal therapy. The selection first offers information on the detection of anti-cancer agents through screening tests and extracellular factors affecting the response of tumors to chemotherapeutic agents. Discussions focus on induced and transplanted tumors, alkylating agents, anti-folics, rate of excretion, dosage regimen, and extra-cellular deactivation. The text then elaborates on intracellular factors influencing the response of tumors t
Normal and malignant cell growth by R. J. M Fry( Book )

3 editions published in 1969 in English and held by 143 WorldCat member libraries worldwide

Aseptic environments and cancer treatment by Georges Mathé( Book )

4 editions published in 1970 in English and held by 135 WorldCat member libraries worldwide

The 1969 Proceedings of the Plenary Session of the European Organization for Research on Treatment of Cancer have been divided between two volumes of a com pletely different nature. Volume 29, Aseptic Environments and Cancer Treatment, deals not only with the treatment of all types of cancer but also with aplastic treatment of bone marrow and certain other pathological conditions, such as immunological insufficiency, bums etc. Hence the volume will be of interest not only to carcinologists and haematologists but also to paediatricians, surgical units, intensive-care units, hospital administrators and architects and engineers who specialize in hospital design and equipment. Volume 30, Advances in the Treatment of Acute (Blastic) Leukemias, deals with a particular form of cancer and will have a more restricted readership of carcinologists specializing in leukemia and all haematologists. Paris, April 1970 GEORGES MATHE Contents Introduction. G. MATHE. 1 Five Years Experience of the Clinical Use of a Pathogen-Free Isolation Unit. G. MATHE, M. SCHNEIDER, 1. SCHWARZENBERG, J. 1. AMIEL, A. CATTAN, J.R. SCHLUMBERGER, M. HAYAT, F. DE VASSAL, CL. JASMIN, and CL. ROSEN- FELD. With 3 Figures . 3 Protected Environments and the Use of Antibiotics. H.E.M. KAY, J. BYRNE, B. JAMESON, and J. LYNCH . 14 Protected Environment, Prophylactic Antibiotics and Cancer Chemotherapy
moreShow More Titles
fewerShow Fewer Titles
Audience Level
Audience Level
  Kids General Special  
Audience level: 0.69 (from 0.65 for Aging and ... to 0.95 for Geschichte ...)

Alternative Names

controlled identitySchweizerische Krebsliga

Association suisse pour la lutte contre le cancer

Associazione svizzera per la lotta contro il cancro

League against Cancer

League against Cancer Schweiz, Schweizerische Nationalliga für Krebsbekämpfung und Krebsforschung

Lega nazionale svizzera contro il cancro

Lega Nazionale Svizzera per la Lotta e lo Studio del Cancro.

Ligue nationale suisse contre le cancer

Ligue Nationale Suisse pour la Lutte Anti-Cancéreuse et la Recherche sur le Cancer.

Ligue nationale suisse pour la lutte anticancéreuse et la recherche sur le cancer



Nationalliga für Krebsbekämpfung und Krebsforschung

Nationalliga für Krebsbekämpfung und Krebsforschung Schweiz

Schweiz. Vereinigung für Krebsbekämpfung

Schweizerische Vereinigung für Krebsbekämpfung


Swiss League against Cancer

Swiss League against Cancer Schweizerische Nationalliga für Krebsbekämpfung und Krebsforschung

Swiss League aganist Cancer